- Open to adults at least 30 years of age at the time of screening with a diagnosis of Parkinson's Disease; must include bradykinesia with sequence effect and motor asymmetry if no rest tremor, and a prominent response to levodopa
- PD medications must be stable for at least 4 weeks prior to screening; MAO-B inhibitors must be stable for at least 12 weeks prior to screening
- Levodopa administration at least 4 times daily (immediate or extended release) or three times daily (Rytary or Crexont)
- Average of 3 hours or more total OFF time/day
- Participants must not have a secondary or atypical parkinsonism, must not have severe or disabling dyskinesia, and must not have had any previous procedure or therapy designed to provide continuous levodopa or stimulation of dopaminergic tone, or anticipation of these during the study
- Current use of strong CYP3A/5 inhibitors or inducers is exclusionary
Detailed eligibility will be reviewed when you contact the study team
This is a randomized clinical research study examining an investigational treatment called CVN424 in patients with Parkinson's Disease (PD).
The purpose of this study is to measure the effects of CVN424 in PD participants experiencing motor fluctuations and dyskinesia. The investigational treatment, CVN424, targets a receptor in the brain that is overactive in PD and believed to contribute to the sensations of stiffness, slowness, unsteadiness, and shaking that many people experience. Researchers in this clinical trial are studying whether CVN424 can potentially reduce that overactivity, and potentially improve the amount of good ON time vs. OFF time that PD patients experience.
Investigational means that CVN424 has not been approved by the U.S. Food and Drug Administration (FDA).
Participants will take the drug orally once daily in the morning.
The study will last around 20 weeks, including screening, treatment, and follow-up periods, with the potential for an open-label extension (OLE) study in the future.